Pro Medicus wins 90m US deal, up 74.6% off its low|analyst says trim, not buy

The Comeback Contract

Pro Medicus has just signed a seven-year, ninety million dollar contract with Beth Israel Lahey Health in Boston, and the stock is up seven point one nine percent to one hundred thirty dollars eighty-nine cents on the news. Its US subsidiary Visage Imaging will roll out its cloud-based Visage 7 platform across fourteen hospitals and more than four thousand seven hundred physicians, with go-live targeted for the first quarter of twenty twenty-seven.

But zoom out and the picture gets more complicated. The wider Pro Medicus share price has now rebounded seventy-four point six percent since bottoming at one hundred eight dollars fifteen cents in February. That rebound followed a brutal slide from an all-time closing high of three hundred thirty dollars forty-eight cents set last July, when a global sell-down in software stocks - the so-called SaaSpocalypse - hit Pro Medicus on fears that artificial intelligence would replace exactly the kind of software it sells. Even after today's pop, the stock remains around forty percent below where it started this year.

So which is the real signal here: the ninety million dollar contract confirming the business is intact, or the forty percent year-to-date hole still under the stock? That is the question the rest of this story has to answer, because the market and at least one analyst who covers this name are answering it very differently today.

The Sell Call Inside the Rally

Alto Capital's Tony Locantro reviewed Pro Medicus after its first-half result and called the numbers exceptional. Underlying earnings before interest and tax rose twenty-nine point seven percent, revenue grew twenty-eight point four percent, and the company secured more than two hundred eighty million dollars in new contract wins. Net profit after tax hit one hundred seventy-one point two million dollars, up two hundred thirty point nine percent year on year.

Despite praising those same numbers, Locantro's conclusion was not to buy - it was to trim. He argued that after a seventy-five percent run from the low, the current risk-reward balance no longer favours holding at full size, because the premium valuation leaves little room for disappointment. That is the paradox: the same earnings beat that the market is using to justify today's rally is the exact evidence the analyst cites for pulling back.

That reframes what today's contract news actually means. A ninety million dollar deal is genuinely good, but if the share price already embeds an expectation of exactly this kind of win, then the news confirms the business without necessarily justifying a new entry. The valuation, not the contract, becomes the variable that decides whether today's buyers are early or late.

What Actually Confirms It

There is one detail in the contract structure worth separating from the headline number. Pro Medicus said the Beth Israel Lahey Health deal is priced on a transactional licensing model, meaning the ninety million dollar figure has upside if actual usage across those fourteen hospitals grows faster than expected. Go-live is targeted for the first quarter of twenty twenty-seven, which means the revenue this contract actually delivers is still ahead of us, not behind us.

For a holder who rode the stock down from three hundred thirty dollars and back up past one hundred eighty, the question is not whether the business is healthy - the result already proved that - it is whether Locantro's valuation ceiling holds. For someone still on the sidelines after missing the seventy-five percent rebound, the entry case improves only if further contract wins keep landing at this pace and usage-based revenue per hospital comes in above what the current price already assumes; if new deal flow slows and the multiple stays this rich with go-live still over a year away, the rally looks more like a valuation catch-up than a fresh re-rating. Track new contract announcements and any early usage disclosures out of Beth Israel Lahey Health before treating today's pop as confirmation.